Disubstituted indazoles as potent antagonists of the integrin α(v)β3

Journal of Medicinal Chemistry

Volumn 43, Issue 1, 2000, Pages 41-58

  Batt, Douglas G ^a   Harlow, Patricia P ^a   Barbera, Frank A ^a   Spitz, Susan M ^a   Wexler, Ruth R ^a   Jadhav, Prabhakar K ^a   Petraitis, Joseph J ^a   Houghton, Gregory C ^a   Modi, Dilip P ^a   Cain, Gary A ^a   Corjay, Martha H ^a   Mousa, Shaker A ^a   Bouchard, Peter J ^a   Forsythe, Mark S ^a  

^a DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 [3 (N IMIDAZOL 2 YLAMINO)PROPYL]INDAZOL 5 YLCARBONYLAMINO] 2 (2,4,6 TRIMETHYLBENZENESULFONYLAMINO)PROPIONIC ACID TRIFLUOROACETATE; FIBRINOGEN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION;

CELL ADHESION; CELL LINE; FIBRINOGEN; HUMANS; INDAZOLES; MODELS, MOLECULAR; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECEPTORS, VITRONECTIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034642520     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990049j     Document Type: Article

References (48)

1. Mousa, S. A.; Cheresh, D. A. Recent Advances in Cell Adhesion Molecules and Extracellular Matrix Proteins: Potential Clinical Implications. Drug Discov. Today 1997, 2, 187-199.
2. Wityak, J.; Sielecki, T. M. Glycoprotein IIb/IIIa Antagonists. Exp. Opin. Ther. Patents 1996, 6, 1175-1194.
3. 3 Integrin "Vitronectin Receptor". Int. J. Biochem. Cell Biol. 1997, 29, 721-725.
4. Chorev, M.; Dresner-Pollak, R.; Eshel, Y.; Rosenblatt, M. Approach to Discovering Novel Therapeutic Agents for Osteoporosis Based on Integrin Receptor Blockade. Biopolymers (Pept. Sci.) 1995, 37, 367-375.
5. Rodan, S. B.; Rodan, G. A. Integrin Function in Osteoclasts. J. Endocrinol. 1997, 154 (Suppl.), S47-S56.
6. Brooks, P. C. Role of Integrins in Angiogenesis. Eur. J. Cancer 1996, 32A, 2423-2429.
7. v-Integrins in Tumour Progression and Metastasis. Sem. Cancer Biol. 1996, 7, 129-138.
8. Strömblad, S.; Cheresh, D. A. Cell Adhesion and Angiogenesis. Trends Cell Biol. 1996, 6, 462-468.
9. Hammes, H.-P.; Brownlee, M.; Jonczyk, A.; Sutter, A.; Preissner, K. T. Subcutaneous Injection of a Cyclic Peptide Antagonist of Vitronectin Receptor-Type Integrins Inhibits Retinal Neovascularization. Nature Med. 1996, 2, 529-533.
10. 3 and Osteopontin Expression During Neointima Formation. Cardiovasc. Res. 1997, 36, 408-428.
11. Topol, E. J.; Califf, R. M.; Weisman, H. F.; Ellis, S. G.; Tcheng, J. E.; Worley, S.; Ivanhoe, R.; George, B. S.; Fintel, D.; Weston, M.; Sigmon, K.; Anderson, K. M.; Lee, K. L.; Willerson, J. T. Randomised Trial of Coronary Intervention with Antibody Against Platelet IIb/IIIa Integrin for Reduction of Clinical Restenosis: Results at Six Months. Lancet 1994, 343, 881-886.
12. The IMPACT-II Investigators. Randomised Placebo-Controlled Trial of the Effect of Epifibatide on Complications of Percutaneous Coronary Intervention: IMPACT-II. Lancet 1997, 349, 1422-1428.
13. The RESTORE Investigators. Effects of Platelet Glycoprotein IIb/IIIa Blockade with Tirofiban on Adverse Cardiac Events in Patients with Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty. Circulation 1997, 96, 1445-1453.
14. Bach, A. C.; Espina, J. R.; Jackson, S. A.; Stouten, P. F. W.; Duke, J. L.; Mousa, S. A.; DeGrado, W. F. Type II′ to Type I β-Turn Swap Changes Specificity for Integrins. J. Am. Chem. Soc. 1996, 118, 293-294.
15. 3 Antagonists. J. Am. Chem. Soc. 1996, 118, 7461-7472.
16. 3) Antagonists. J. Med. Chem. 1997, 40, 2289-2292.
17. 3) Antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 3165-3170.
18. 3) Antagonist With Efficacy in a Restenosis Model. Bioorg. Med. Chem. Lett. 1998, 8, 3171-3176.
19. 3 Inhibits Leydig Cell Tumor Growth and the Development of Hypercalcemia of Malignancy. Cancer Res. 1998, 58, 1930-1935.
20. 3 as Inhibitors of Bone Resorption. American Chemical Society 211th National Meeting, New Orleans, LA, 1996; MEDI 234.
21. 3 Antagonist Lead Compounds. Bioorg. Med. Chem. Lett. 1999, 9, 937-942.
22. 3. J. Med. Chem. 2000, 43, 27-40.
23. Xue, C.-B.; Roderick, J.; Jackson, s.; Rafalski, M.; Rockwell, A.; Mousa, S.; Olson, R. E.; DeGrado, W. F. Design, Synthesis and In Vitro Activities of Benzamide-Core Glycoprotein IIb/IIIa Antagonists: 2,3-Diaminopropionic Acid Derivatives as Surrogates of Aspartic Acid. Bioorg. Med. Chem. 1997, 5, 693-705.
24. Askew, B. C.; Bednar, R. A.; Bednar, B.; Claremon, D. A.; Cook, J. J.; McIntyre, C. J.; Hunt, C. A.; Gould, R. J.; Lynch, R. J.; Lynch, J. J.; Gaul, S. L.; Stranieri, M. T.; Sitko, G. R.; Holahan, M. A.; Glass, J. D.; Hamill, T.; Gorham, L. M.; Prueksaritanont, T.; Baldwin, J. J.; Hartman, G. D. Non-Peptide Glycoprotein IIb/ IIIa Inhibitors. 17. Design and Synthesis of Orally Active, Long-Acting Non-Peptide Fibrinogen Receptor Antagonists. J. Med. Chem. 1997, 40, 1779-1788.
25. Mokotoff, M.; Logue, L. W. Potential Inhibitors of L-Asparagine Biosynthesis. 5. Electrophilic Amide Analogues of (S)-2,3-Diaminopropionic Acid. J. Med. Chem. 1981, 24, 554-559.
26. Sakai, N.; Ohfune, Y. Total Synthesis of Galantin I. Acid-Catalyzed Cyclization of Galantinic Acid. J. Am. Chem. Soc. 1992, 114, 998-1010.
27. Ried, W.; Wagner, K. Reaction of o-Quinonediazides with Ketene. Liebigs Ann. Chem. 1965, 681, 45-51.
28. Brown, F. J.; Yee, Y. K. Heterocyclic Carboxamides. Eur. Pat. Appl. 242, 167, 1987.
29. Bartsch, R. A.; Yang, I.-W. Phase Transfer Catalyzed Synthesis of Indazoles from o-Alkylbenzenediazonium Tetrafluoroborates. J. Heterocycl. Chem. 1984, 21, 1063-1064.
30. Rüchardt, C.; Hassmann, V. Aromatic Diazonium Salts X. A One-Pot Procedure for the Jacobson Synthesis of Indazoles. Liebigs Ann. Chem. 1980, 908-927.
31. Auwers, K. v.; Schaich, W. N-Alkyl Derivatives and N-Carboxylate Esters of Indazole. Chem. Ber. 1921, 54, 1738-1770.
32. Albini, A.; Bettinetti, G.; Minoli, G. Pyrazolo[1,2-alindazole and its Reaction with Dimethyl Acetylenedicarboxylate. Heterocycles 1988, 27, 1207-1216.
33. Seela, F.; Bourgeois, W. Stereoselective Synthesis of Indazole 2′-Deoxy-β-D-ribonucleosides: Glycosylation of the Nucleobase Anion. Helv. Chim. Acta 1991, 74, 315-322.
34. Rousseau, V.; Lindwall, H. G. Structure and Ultraviolet Absorption Spectra of Indazole, 3-Substituted Indazole and Some of Their Derivatives. J. Am. Chem. Soc. 1950, 72, 3047-3051.
35. Secrist, J. A., III; Logue, M. W. Amine Hydrochlorides By Reduction in the Presence of Chloroform. J. Org. Chem. 1972, 37, 335-336.
36. Misra, R. N.; Kelly, Y. F.; Brown, B. R.; Roberts, D. G. M.; Chong, S.; Seiler, S. M. Argatroban Analogues: Synthesis, Thrombin Inhibitory Activity and Cell Permeability of Aminoheterocyclic Guanidine Surrogates. Bioorg. Med. Chem. Lett. 1994, 4, 2165-2170.
37. Bettesworth, N. J.; Smith, M.; Perrior, T. R.; Whittle, A. J.; Williams, A. J.; Moseley, D. W. Pyrimidines. U.S. Pat. 5,109,-004, 1992.
38. Hartman, G. D.; Egbertson, M. S.; Halczenko, W.; Laswell, W. L.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; Manno, P. D.; Lynch, R. J.; Zhang, G.; Chang, C. T. C.; Gould, R. J. Non-Peptide Fibrinogen Receptor Antagonists. 1. Discovery and Design of Exosite Inhibitors. J. Med. Chem. 1992, 35, 4640-4642.
39. Xue, C.-B.; Wityak, J.; Sielecki, T. M.; Pinto, D. J.; Batt, D. G.; Cain, G. A.; Sworin, M.; Rockwell, A. L.; Roderick, J. J.; Wang, S.; Orwat, M. J.; Frietze, W. E.; Bostrom, L. L.; Liu, J.; Higley, C. A.; Rankin, F. W.; Tobin, A. E.; Emmett, G.; Lalka, G. K.; Sze, J. Y.; Di Meo, S. V.; Mousa, S. A.; Thoolen, M. J.; Racanelli, A. L.; Hausner, E. A.; Reilly, T. M.; De Grado, W. F.; Wexler, R. R.; Olson, R. E. Discovery of an Orally Active Series of Isoxazoline Glycoprotein IIb/IIIa Antagonists. J. Med. Chem. 1997, 40, 2064-2084.
40. Olson, R. E.; Sielecki, T. M.; Wityak, J.; Pinto, D. J.; Batt, D. G.; Frietze, W. E.; Liu, J.; Tobin, A. E.; Orwat, M. J.; Di Meo, S. V.; Houghton, G. C.; Lalka, G. K.; Mousa, S. A.; Racanelli, A. L.; Hausner, E. A.; Kapil, R. P.; Thoolen, M. J.; Reilly, T. M.; Anderson, P. S.; Wexler, R. R. Orally Active Isoxazoline Glycoprotein IIb/IIIa Antagonists with Extended Duration of Action. J. Med. Chem. 1999, 42, 1178-1192.
41. Mousa, S.; Forsythe, M.; Lorelli, W.; Bozarth, J.; Xue, C.-B.; Wityak, J.; Sielecki, T.; Olson, R.; DeGrado, W.; Wexler, R.; Thoolen, M.; Reilly, T. M. Discovery of Novel Nonpeptide Antiplatelet GPIIb/IIIa Receptor Antagonist, DMP754: Receptor Binding Affinity and Specificity. Coronary Artery Dis. 1996, 7, 767-774.
42. 3 Integrin Binding Affinity and Specificity of SM256 in Various Species. J. Cardiovasc. Pharmacol. 1999, 33, 641-646.
43. Elguero, J. Pyrazoles and Their Benzo Derivatives. In Comprehensive Heterocyclic Chemistry; Potts, K. T., Ed.; Pergamon Press: New York, 1984; Vol. 5, Chapter 4.04, pp 210-216.
44. Kerr, J. S.; Wexler, R. S.; Mousa, S. A.; Robinson, C. S.; Wexler, E. J.; Mohamed, S.; Voss, M. E.; Devenny, J. J.; Czerniak, P. M.; Gudzelak, A.; Slee, A. M. Novel Small Molecule Alpha v Integrin Antagonists: Comparative Anti-cancer Efficacy With Known Angiogenesis Inhibitors. Anticancer Res. 1999, 19, 959-968.
45. Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for Preparative Separations With Moderate Resolution. J. Org. Chem. 1978, 43, 2923-2925.
46. Herre, A. Thionyl Derivatives of some Aromatic Amidoesters. Chem. Ber. 1895, 28, 593-600.
47. Krapcho, A. P.; Kuell, C. S. Monoprotected Diamines. N-tert-Butoxycarbonyl-α,ω-Alkanediamines From α,ω-Alkanediamines. Synth. Commun. 1990, 20, 2559-2564.
48. Mousa, S. A.; Bozarth, J. M.; Forsythe, M. S.; Jackson, S. M.; Leamy, A.; Diemer, M. M.; Kapil, R. P.; Knabb, R. M.; Mayo, M. C.; Pierce, S. K.; De Grado, W. F.; Thoolen, M. J.; Reilly, T. M. Antiplatelet and Antithrombotic Efficacy of DMP 728, a Novel Platelet GPIIb/IIIa Receptor Antagonist. Circulation 1994, 89, 3-12.